阿波利波蛋白E4对帕金森病认知功能的影响:PPMI队列中的结构性MRI研究
Angenelle Eve Rosal1,2, Edgardo Torres-Carmona2,3, Sarah L Martin1
1Brain Health Imaging Centre, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
PloS one
|January 20, 2026
概括
在早期帕金森病 (PD) 中,阿波利波蛋白E4 (APOE4) 基因变异可能不会影响大脑结构变化,例如灰质体积. 需要进一步的纵向研究来证实APOE4在PD认知功能中的作用.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 神经学 神经学
背景情况:
- 认知障碍是帕金森病 (PD) 中常见的一种非运动性症状,其潜在机制尚不清楚.
- 遗传风险因子Apolipoprotein E4 (APOE4) 与PD认知障碍有关,但研究结果不一致.
- 之前的神经成像研究表明,PD患者和APOE4携带者的灰质异常,但APOE4的具体作用仍然未得到充分研究.
研究的目的:
- 调查APOE4是否影响在认知上未受损的帕金森病患者的早期结构性大脑差异 (灰质体积和皮质厚度).
- 确定这些结构性大脑变化与与APOE4状态相关的认知表现之间的关联.
主要方法:
- 利用来自51名携带APOE4和120名非携带认知无损的帕金森病患者的数据,这些数据来自帕金森病进展标志物倡议 (PPMI) 数据库.
- 分析了T1加权的MRI扫描,以计算大脑关键区域的灰质体积 (GMV) 和皮质厚度 (CTh),包括海马子区域.
- 与认知分数相关的区域GMV和CTh评估全球认知和特定领域的认知分数.
主要成果:
- 与非携带者相比,APOE4携带者显示左角环GMV增加和左核accumbensGMV减少,但这些并没有在多次比较的纠正中存活下来.
- 左角环GMV与视觉空间功能相关;左核accumbensGMV与非载体的视觉空间功能和工作记忆相关,但在同变量调整后,这些关联并不始终显著.
- 在皮层厚度或海马亚区灰质体积方面没有观察到显著的群体差异.
结论:
- 在帕金森病中,APOE4可能不会显著影响与认知功能相关的早期结构性大脑变化 (GMV,CTh).
- 观察到的特定大脑区域与认知功能之间的相关性需要进一步研究,特别是在纵向研究中.
- 需要进行纵向分析来证实这些发现,并充分阐明APOE4在PD认知轨迹中的作用.
相关概念视频
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...